Cetera Investment Advisers’s Immunic IMUX Stock Holding History

Cetera Investment Advisers’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,600	Closed	-$23.8K	–	2256
2023 Q1	$23.8K	Buy	+1,600	New	+$29.7K	﹤0.01%	2117

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Cetera Investment Advisers's IMUX Position: Q2 2023 in Review

Cetera Investment Advisers sold out of Immunic (IMUX) in Q2 2023, closing a stake of 1,600 shares — an estimated $23.8K sold.

Cetera Investment Advisers first reported a position in IMUX in Q1 2023 and held it in 1 quarter. The position peaked at $23.8K in Q1 2023. 63 funds tracked by Wall St. Rank hold IMUX as of Q2 2023.

Cetera Investment Advisers reported no remaining Immunic position as of Q2 2023 after selling out during the quarter.
Cetera Investment Advisers sold 1,600 Immunic shares in Q2 2023, an estimated $23.8K.
Cetera Investment Advisers first reported a position in Immunic in Q1 2023 and held it in 1 quarter.
Cetera Investment Advisers's Immunic position peaked at $23.8K in Q1 2023.
63 funds tracked by Wall St. Rank held Immunic as of Q2 2023.

Based on Cetera Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.